Expanded Access to Telisotuzumab Vedotin
NCT04830202 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-05-13
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
Interventions
- DRUG
-
Telisotuzumab vedotin
Intravenous Infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT05513703 ·Status: TERMINATED ·Phase: PHASE2
-
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
NCT07323641 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
NCT06093503 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01386385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00334815 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT04225117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
NCT00065182 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00541099 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
NCT06834074 ·Status: AVAILABLE
-
Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00387699 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
NCT04884282 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704 ·Status: TERMINATED ·Phase: PHASE2
-
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00828009 ·Status: COMPLETED ·Phase: PHASE2
-
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
NCT07322341 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT01966003 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
NCT04989283 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00666692 ·Status: COMPLETED ·Phase: PHASE1
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401 ·Status: RECRUITING ·Phase: PHASE3
-
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
NCT04364620 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3